Rajan P. Kulkarni

Oregon Health & Science University — United States

Medicine · Health Sciences

37h-index6.5kcitations118works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(21), Microfluidic and Bio-sensing Technologies(16), Advanced Fluorescence Microscopy Techniques(13), Cancer Immunotherapy and Biomarkers(11), Cancer Genomics and Diagnostics(10)

Publications118 total

The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors
Nature reviews. Cancer·2025· 2 cited
A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma
Cell Reports·2025Open Access
Bridging single cells to organs: Mesoscale modules as fundamental units of tissue function
Cell·2025· 1 citedOpen Access
Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1
JCI Insight·2025· 3 citedOpen Access
Next-gen tools in cancer neuroscience
Cell Reports·2025· 1 citedOpen Access
0426 UAZ22-10-01: A Phase IIa single-arm open-label clinical trial of calcipotriene plus 5-fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients
Journal of Investigative Dermatology·2025· 1 citedOpen Access
<scp>MIF</scp> as an oncogenic driver of low‐heterogeneity melanomas
Molecular Oncology·2025Open Access
Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy
Cancers·2025· 8 citedOpen Access
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Oncotarget·2024· 9 citedOpen Access
839 The genomic evolution of tumor cell phenotypic plasticity: Can we inhibit skin cancer adaptability itself?
Journal of Investigative Dermatology·2024Open Access
MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Cancers·2024· 22 citedOpen Access
Comparison of Immunotherapy versus Targeted Therapy Effectiveness in BRAF-Mutant Melanoma Patients and Use of cGAS Expression and Aneuploidy as Potential Prognostic Biomarkers
Cancers·2024· 3 citedOpen Access
Optimization of Tissue Digestion Methods for Characterization of Photoaged Skin by Single Cell RNA Sequencing Reveals Preferential Enrichment of T Cell Subsets
Cells·2024· 3 citedOpen Access
UNDERSTANDING THE DYNAMICS OF ENVIRONMENT, PANCHMAHABHUTA AND HUMAN PHYSIOLOGY IN AYURVEDA
International journal of Indian medicine·2024Open Access
Computational assessment of T cell plasticity in immune-related adverse events
Faculty of 1000 Research Ltd·2024Open Access
Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
JAMA Network Open·2023· 40 citedOpen Access
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Journal for ImmunoTherapy of Cancer·2023· 49 citedOpen Access
Advances in Early Detection of Melanoma and the Future of At-Home Testing
Life·2023· 38 citedOpen Access
Modeling collective cell behavior in cancer: Perspectives from an interdisciplinary conversation
Cell Systems·2023· 11 citedOpen Access
Early Detection and Prognostic Assessment of Cutaneous Melanoma
JAMA Dermatology·2023· 33 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Dino Di Carlo(12), Yichen Ding(8), Tzung K. Hsiai(8), James Che(7), Jonathan W. Goldman(6), Scott E. Fraser(5), Melissa Matsumoto(5), Kevin Sung(5), Matthew B. Rettig(4), Manjima Dhar(4), Corinne Renier(4), Edward B. Garon(4), Stefanie S. Jeffrey(4), Jianguo Ma(4), Elodie Sollier(3), Derek E. Go(3), Jianyu Rao(3), Mark E. Davis(3), Reza Ardehali(3), Edward Pao(3)